NanoViricides (NYSE-A:NNVC) told investors it believes that the strong safety and tolerability of its NV-CoV-2 oral drug products containing the active ingredient NV-387 shows that they have implications beyond COVID.
NV-387 is an ultra-broad-spectrum antiviral nanomedicine that was designed by copying a common host-side chemical signature used by viruses to infect and cause disease in humans and animals, the company said.
The company recently reported positive safety data from a Phase 1a/1b trial of NV-387 in humans.
Not only did no patients in the study experience any adverse events, but NV-387 demonstrated early signs of effectiveness against respiratory viruses, including coronaviruses and respiratory syncytial virus (RSV).
The company believes the comparable features of its NanoViricides (NYSE-A:NNVC) technology platform, in particular NV-387, with the development of antibiotics like penicillin against bacteria demonstrates it is positioned to revolutionize the treatment of antiviral infections.
"We believe that the strong demonstration of safety and tolerability in the clinical trial sets NV-387 on a path of long-term success against many viruses," NanoViricides (NYSE-A:NNVC) president and executive chairman Dr. Anil R. Diwan said in a statement.
"We believe NanoViricides platform is now on a solid footing to revolutionize treatment of antiviral infections just as antibiotics like penicillin revolutionized treatment of bacterial infections."
Analysts at EFHutton agree with NanoViricides’ thesis, in a recent note to clients highlighting the potential of its technology to have revenue-generating potential in more than a dozen diseases or illnesses.
“We expect that initial potential revenues could be from milestone payments beginning in 2026 from other indications such as Smallpox, Mpox, Herpes, RSV, Shingles and several other non-coronavirus viruses or diseases,” the analysts wrote.
NanoViricides is a clinical-stage company that is creating special-purpose nanomaterials for antiviral therapy.